FDA embraces the first US application for a gene therapy, offering an accelerated test case – Endpoints News
Endpoints News |
FDA embraces the first US application for a gene therapy, offering an accelerated test case
Endpoints News If the approval does come through, Spark will be in the lead in establishing a reimbursement model for a gene therapy in a market dominated by multiple payers. UniQure tried and failed in Europe with Glybera and now GSK is following up making slow … Spark Therapeutics' Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA |
